Zafgen, a biotech developing a treatment for severe obesity and hunger-related disorders, raised $96 million by offering 6 million shares (upsized from 5 million) at $16, the high end of the range of $14 to $16. Zafgen plans to list on the NASDAQ under the symbol ZFGN. Zafgen initially filed confidentially on 1/31/2014. Leerink Partners and Cowen & Company acted as lead managers on the deal.